Advertisement
U.S. markets closed
  • S&P Futures

    5,089.50
    -0.50 (-0.01%)
     
  • Dow Futures

    38,991.00
    -25.00 (-0.06%)
     
  • Nasdaq Futures

    18,009.75
    -11.25 (-0.06%)
     
  • Russell 2000 Futures

    2,057.20
    -2.70 (-0.13%)
     
  • Crude Oil

    78.58
    -0.29 (-0.37%)
     
  • Gold

    2,039.80
    -4.30 (-0.21%)
     
  • Silver

    22.41
    -0.12 (-0.54%)
     
  • EUR/USD

    1.0840
    -0.0008 (-0.08%)
     
  • 10-Yr Bond

    4.3150
    +0.0160 (+0.37%)
     
  • Vix

    13.43
    -0.31 (-2.26%)
     
  • GBP/USD

    1.2671
    -0.0015 (-0.12%)
     
  • USD/JPY

    150.4560
    -0.0240 (-0.02%)
     
  • Bitcoin USD

    56,942.99
    +491.54 (+0.87%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,683.02
    -1.28 (-0.02%)
     
  • Nikkei 225

    39,191.99
    -47.53 (-0.12%)
     

Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Jackson Center, Pennsylvania--(Newsfile Corp. - April 4, 2022) - Halberd Corporation (OTC Pink: HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression - C-Reactive Protein1. According to the National Institute of Mental Health, "Major depression is one of the most common mental disorders in the United States."2 An estimated 21 million Americans experienced at least one major depression episode in 2020. This represents about 8.4% of the population.

In the recent past, scientists, now part of Halberd, worked with the military to attempt to stem the rash of suicides associated with clinical depression due to PTSD/TBI.

Associated Antigens

PTSD/CTE/ Depression

Neurodegenerative Diseases*

Phosphorylated Tau

Completed

Completed

IL-6

Completed

Completed

TNF-α

Completed

Completed

IL-1

N/A

Completed

IL-12

N/A

Completed

IL-2

N/A

Completed

Beta Amyloid

N/A

Completed

IL-4

N/A

Completed

Tau

Completed

Completed

Glutamate

Completed

Completed

C-Reactive Protein

Completed

N/A

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "In patients with major clinical depression, numerous peer reviewed medical studies have shown increased levels of CRP, IL-6, IL-1 and TNF-alpha. These findings have also been corroborated by meta-analysis studies. Lowering the CSF level of these specific target antigens should greatly improve the clinical state of patients with PTSD and suicidal ideation. Halberd's in-vitro laboratory tests have achieved that long sought-after goal!"

William A. Hartman, Halberd's Chairman, President & CEO added, "Halberd's achievements in the entire neurodegenerative disease project have been truly historic! It is estimated that almost 40 million Americans are currently suffering some form of neurodegenerative disease. We have developed a step-by-step plan to convert our laboratory successes into a commercial product/process. There are certain business developments pending which could expedite these plans. In the interim, we will continue our laboratory experimentation on blood serum and plasma and then move forward with animal testing. We expect to announce some very exciting developments in that regard in the next several weeks."

To get the latest news on Halberd's exciting developments, including our ongoing disease eradication accomplishments, subscribe by submitting this form.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter: @HalberdC

About Halberd Corporation.
Halberd Corporation (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed twenty related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Company undertakes no obligation to revise these statements following the date of this news release.


1 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3741070/
2 https://www.nimh.nih.gov/health/statistics/major-depression

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/119101

Advertisement